UA4773U - Соединение 5-[(4-хлорфенил)метилиден]-2-(4-оксианилино)-4,5-дигидротиазол-4-он, которое проявляет противоопухолевую активность - Google Patents
Соединение 5-[(4-хлорфенил)метилиден]-2-(4-оксианилино)-4,5-дигидротиазол-4-он, которое проявляет противоопухолевую активность Download PDFInfo
- Publication number
- UA4773U UA4773U UA2004031889U UA2004031889U UA4773U UA 4773 U UA4773 U UA 4773U UA 2004031889 U UA2004031889 U UA 2004031889U UA 2004031889 U UA2004031889 U UA 2004031889U UA 4773 U UA4773 U UA 4773U
- Authority
- UA
- Ukraine
- Prior art keywords
- oxyanilino
- chlorophenyl
- methylidene
- dihydrothiazol
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 12
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 title abstract description 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 title description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 5
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 201000002364 leukopenia Diseases 0.000 description 4
- 231100001022 leukopenia Toxicity 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- RAYUAJGVGHMQCV-UHFFFAOYSA-N ethyl 2-[(4-oxo-1,3-thiazol-2-yl)sulfanyl]acetate Chemical compound CCOC(=O)CSC1=NC(=O)CS1 RAYUAJGVGHMQCV-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- FZJCXIDLUFPGPP-UHFFFAOYSA-N propan-2-ol;toluene Chemical compound CC(C)O.CC1=CC=CC=C1 FZJCXIDLUFPGPP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 150000003548 thiazolidines Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- -1 (4-chlorophenyl)methylidene Chemical group 0.000 description 1
- FJYYWRQKUXJNMW-UHFFFAOYSA-N 3-[bis(aziridin-1-yl)phosphoryl]-2-methyl-1,3-thiazolidine Chemical compound CC1SCCN1P(=O)(N1CC1)N1CC1 FJYYWRQKUXJNMW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101001024442 Cellulomonas fimi Beta-N-acetylglucosaminidase/beta-glucosidase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101000844611 Metallosphaera sedula (strain ATCC 51363 / DSM 5348 / JCM 9185 / NBRC 15509 / TH2) DNA-binding protein 7 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QAXZWHGWYSJAEI-UHFFFAOYSA-N n,n-dimethylformamide;ethanol Chemical compound CCO.CN(C)C=O QAXZWHGWYSJAEI-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000002079 spinocerebellar ataxia with epilepsy Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Полезная модель касается синтеза соединения 5-[(4-хлорфенил)метилиден]-2-(4-оксианилино)-4,5-дигидротиазол-4-он формулы: , которая проявляет противоопухолевую активность.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2004031889U UA4773U (ru) | 2004-03-15 | 2004-03-15 | Соединение 5-[(4-хлорфенил)метилиден]-2-(4-оксианилино)-4,5-дигидротиазол-4-он, которое проявляет противоопухолевую активность |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2004031889U UA4773U (ru) | 2004-03-15 | 2004-03-15 | Соединение 5-[(4-хлорфенил)метилиден]-2-(4-оксианилино)-4,5-дигидротиазол-4-он, которое проявляет противоопухолевую активность |
Publications (1)
Publication Number | Publication Date |
---|---|
UA4773U true UA4773U (ru) | 2005-02-15 |
Family
ID=74493661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2004031889U UA4773U (ru) | 2004-03-15 | 2004-03-15 | Соединение 5-[(4-хлорфенил)метилиден]-2-(4-оксианилино)-4,5-дигидротиазол-4-он, которое проявляет противоопухолевую активность |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA4773U (ru) |
-
2004
- 2004-03-15 UA UA2004031889U patent/UA4773U/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Karakurt et al. | Synthesis of some 1-(2-naphthyl)-2-(imidazole-1-yl) ethanone oxime and oxime ether derivatives and their anticonvulsant and antimicrobial activities | |
FI81096C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(n-substituerad guanidino)-4-heteroaryltiazolfoereningar. | |
WO2005105805A9 (fr) | Carbamoylase-heterocycles anneles, bibliotheque focalisee, compositions pharmaceutiques et procedes de fabrication correspondants | |
JPS62294653A (ja) | 新規なジスタマイシンa同族体、その製造方法およびそれを含有する医薬組成物 | |
NL8202626A (nl) | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. | |
KR20220079866A (ko) | 치료 접합체 | |
Ozkirimli et al. | Synthesis of new triazolyl-N, N-dialkyldithiocarbamates as antifungal agents | |
US20090312324A1 (en) | Compositions and Methods Related to RAD51 Inactivation in the Treatment of Neoplastic Diseases, and Especially CML | |
US7288545B2 (en) | Piperazinedione compounds | |
KR20130118731A (ko) | 항증식성 질환 치료에 사용하기 위한 pi3k 억제제로서 피페라지노트리아진 | |
Kaplancikli et al. | Synthesis and antituberculosis activity of new 3-alkylsulfanyl-1, 2, 4-triazole derivatives | |
UA4773U (ru) | Соединение 5-[(4-хлорфенил)метилиден]-2-(4-оксианилино)-4,5-дигидротиазол-4-он, которое проявляет противоопухолевую активность | |
JP2686961B2 (ja) | 耐腫瘍活性を有する新規な1−アルキル−1−スルホニル−2−アルコキシカルボニルスルフェニルヒドラジン | |
FR3001967A1 (fr) | Procede de fabrication de pyrazoles, nouveaux pyrazoles et leurs applications | |
RU2654201C1 (ru) | N,n'-(алкандиил)бис[лабда-7(9),13,14-триен-4-карбоксамиды], обладающие противоопухолевой активностью | |
JP6927959B2 (ja) | ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法 | |
CN113105459B (zh) | 一种三唑并嘧啶衍生物及其制备方法和应用 | |
RU2607920C2 (ru) | Этиловые эфиры 2-амино-1-бензоиламино-4-оксо-5-(2-оксо-2-арил-этилиден)-4,5-дигидро-1h-пирролидин-3-карбоновых кислот, проявляющие противоопухолевую активность, и способ их получения | |
JPH0637468B2 (ja) | 殺生物多環化合物およびそれらを含有する医薬製剤 | |
EP4132657A1 (en) | Compositions and methods for treatment of anticancer-drug resistant cancers | |
KR20210146296A (ko) | 티민 핵산 염기를 베이스로 하는 트리아졸로피리미딘류 및 그 제조 방법 | |
WO1999032115A1 (en) | Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof | |
NL8703148A (nl) | Pyrimidinederivaten. | |
JPS63264580A (ja) | 3−(2−ハロアルキル)−1,4−オキサチインおよび2−(2−ハロアルキル)−1,4−ジチイン | |
Kataev et al. | Synthesis and Hypotensive Activity of Pyrimidine-2, 4-(1 H, 3 H)-Dione Derivatives Containing Thietane Rings with Sulfur in Various Oxidation States |